Medtronic and Abbott Jointly Announce In-Depth Collaboration in Diabetes Field, Featuring Leading CGM ProductsFreeStyle Libre Integrated into Medtronic'sAutomatic Insulin Delivery (AID) and smart insulin pens create a 1+1>2 effect."This partnership brings together two global leaders in glucose sensing technology and insulin delivery."FreeStyle LibreTechnology sets the standard for accurate, easy-to-use, and reliable continuous glucose monitoring. Connected to Medtronic.Auto InsulinPump（AID）"CGM built with algorithms allows people to spend less time thinking about diabetes and more time living."---Jared Watkin Executive Vice President of Abbott's Diabetes Care BusinessCut"Our collaboration with Abbott enables us to expand our access to advancedAuto insulinPump（AID）AndSmart Insulin PenThese systems are able to provide top-tier results for the most widely used CGM in the world. We are committed to simplifying diabetes management, allowing those who aim for greater achievements in diabetes care to transition more seamlessly into automated technology."
---Que Dallara Executive Vice President and President of Medtronic DiabetesThere has always been such a saying in the medical industry“Unless on the road to the underworld, this lifeKing avoids King”. Various actions asDiabetes细分领域The Kings: Medtronic (Insulin Pump) and Abbott (CGM)Epic collaboration will not only expand market share across various fields but also effectively counter various competitors.。Medtronic's Automated Insulin Pump (AID) is currently the insulin pump with the most users in the market, with an estimated global user base of over 11 million. However, Medtronic faces strong competitors such as Insulet, Roche, and Tandem. Particularly, Insulet’s disposable wearable insulin patch pump—Omnipod—has posed a significant challenge to Medtronic’sMiniThe Med series is a bit overwhelmed. Last yearInSulet relies onOmnipod Achieves$1.7 billionSales, largely eating into Medtronic's original market share.To this end, last year Medtronic announced a...Brain Acquisition, Acquisition of Korean Company EOFlow. Ultimately, due to serious intellectual property risks associated with EOFlow and its product EOPatch in relation to Insulet, Medtronic had to withdraw its acquisition commitment. This led to Medtronic's inability to obtain the latest...Insulin Patch Pump Technology, to the Extent That the Market No Longer Favors MedtronicFutureLeadership in the diabetes field.Therefore, Medtronic urgently needs to introduce new technologies to improve itsAutomatic InsulinPump(AID) and the technical competitiveness of smart insulin pens. Previously, Medtronic exclusively used its own CGM.`, its latest CGM product Simplera received FDA approval for market launch in September last year. However, the performance of Simplera...`The gap with the top CGM products on the market is too large. Simplera, like the previous generation Guardian 4, has a MARD of 10.2%. In contrast, Dexcom G7 has a MARD of 8.2%, and FreeStyle Libre 3 boasts even higher accuracy with a MARD of 7.9%. The poor accuracy of Simplera also weakens the market competitiveness of MiniMed 780G and InPen.
FreeStyle LibrThe E-series and Lingo are Abbott's cash cows. Last year, Abbott achieved $5.7 billion in sales solely from the FreeStyle Libre series. Although Abbott is currently the leading player in the CGM market, it faces strong competition from Dexcom, Roche, Senseonics, and other rivals, especially...Dexcom in terms of technology and market (last year's sales also reached$3.62 billion, with a growth rate as high as 24%) are not inferior to Abbott, and even lead in some technologies. This has put immense pressure on Abbott.When Wang and Wang face concerns about the future, the two finally join forces. Especially Medtronic, through cooperation with Abbott, will enable itThe performance of Automated Insulin Delivery (AID) systems and smart insulin pens has significantly improved, greatly enhancing patients' health and quality of life. Abbott will develop a proprietary CGM product for Medtronic, which will be responsible for its sales. The new CGM will enableMiniMed 780G achieves automatic insulin adjustment to keep blood glucose levels within the optimal range.
Looking forward to the new CGM pairingMiniMed 780G can bring a brand-new experience to diabetes patients and improve their health.
